Study of BHV-1300 in Graves' Disease
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06980649
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 550
- Registration Number
- NCT06976268
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 95
- Registration Number
- NCT06874335
- Locations
- 🇺🇸
Site-103, Austin, Texas, United States
🇺🇸Site-105, San Antonio, Texas, United States
🇺🇸Site-102, Fairfax, Virginia, United States
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 575
- Registration Number
- NCT06603623
- Locations
- 🇺🇸
MD First Research, Gilbert, Arizona, United States
🇺🇸WR-PRI, LLC (Encino), Encino, California, United States
🇺🇸Cenexel CNS Los Alamitos, Los Alamitos, California, United States
Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 909
- Registration Number
- NCT06529146
- Locations
- 🇺🇸
Biohaven, New Haven, Connecticut, United States
Long-term Safety and Tolerability of BHV-7000
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 660
- Registration Number
- NCT06443463
- Locations
- 🇪🇸
Hospital Ruber Internacional (Grupo Quironsalud), Madrid, Spain
🇪🇸Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
🇪🇸Hospital Regional Universitario de Malaga - Hospital General, Málaga, Spain
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 242
- Registration Number
- NCT06425159
- Locations
- 🇫🇷
Hôpital Pontchaillou, Rennes, France
🇺🇸Accel Research, Birmingham, Alabama, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
BHV-7000 Open-Label Extension Bipolar Mania Study
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06423794
- Locations
- 🇺🇸
CIT IE, Riverside, California, United States
🇺🇸Uptown Research Institute, Chicago, Illinois, United States
🇺🇸Pillar Clinical Research, Chicago, Illinois, United States
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT06423781
- Locations
- 🇺🇸
Reverie Mind, LLC, Chandler, Arizona, United States
🇺🇸IMA Clinical Research, Las Vegas, Nevada, United States
🇺🇸Pillar Clinical Research, LLC, Little Rock, Arkansas, United States
BHV-7000 Acute Treatment of Bipolar Mania
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 274
- Registration Number
- NCT06419582
- Locations
- 🇺🇸
Pillar Clinical Research, LLC, Richardson, Texas, United States
🇺🇸WIRG, Little Rock, Arkansas, United States
🇺🇸WRN, Rogers, Arkansas, United States